Recombinant human anti-OX40 monoclonal antibody (Livzon Group)

重组全人源抗OX40单克隆抗体（丽珠集团）

Report date: 2022/07/07 10:09:31

Base Information

Drug NameRecombinant human anti-OX40 monoclonal antibody (Livzon Group)

Drug Alias Name重组全人源抗OX40单克隆抗体注射液

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionTumor necrosis factor receptor superfamily member 4 agonists

TargetsTumor necrosis factor receptor superfamily member 4

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

China Registration ClassClass 1 therapeutic biologic in China

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

ATC CodeN/A